235 related articles for article (PubMed ID: 11162316)
1. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors.
Xu K; Ma H; McCown TJ; Verma IM; Kafri T
Mol Ther; 2001 Jan; 3(1):97-104. PubMed ID: 11162316
[TBL] [Abstract][Full Text] [Related]
2. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
3. High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector.
Gao Z; Golob J; Tanavde VM; Civin CI; Hawley RG; Cheng L
Stem Cells; 2001; 19(3):247-59. PubMed ID: 11359950
[TBL] [Abstract][Full Text] [Related]
4. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods.
Sastry L; Johnson T; Hobson MJ; Smucker B; Cornetta K
Gene Ther; 2002 Sep; 9(17):1155-62. PubMed ID: 12170379
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral vectors: regulated gene expression.
Kafri T; van Praag H; Gage FH; Verma IM
Mol Ther; 2000 Jun; 1(6):516-21. PubMed ID: 10933976
[TBL] [Abstract][Full Text] [Related]
6. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors.
Cockrell AS; Ma H; Fu K; McCown TJ; Kafri T
Mol Ther; 2006 Aug; 14(2):276-84. PubMed ID: 16516556
[TBL] [Abstract][Full Text] [Related]
7. Self-inactivating lentiviral vectors with U3 and U5 modifications.
Iwakuma T; Cui Y; Chang LJ
Virology; 1999 Aug; 261(1):120-32. PubMed ID: 10441560
[TBL] [Abstract][Full Text] [Related]
8. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses.
Kuate S; Stefanou D; Hoffmann D; Wildner O; Uberla K
J Gene Med; 2004 Nov; 6(11):1197-205. PubMed ID: 15459964
[TBL] [Abstract][Full Text] [Related]
9. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters.
Pluta K; Luce MJ; Bao L; Agha-Mohammadi S; Reiser J
J Gene Med; 2005 Jun; 7(6):803-17. PubMed ID: 15655804
[TBL] [Abstract][Full Text] [Related]
10. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.
Pacchia AL; Adelson ME; Kaul M; Ron Y; Dougherty JP
Virology; 2001 Mar; 282(1):77-86. PubMed ID: 11259192
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel trans-lentiviral vector that affords predictable safety.
Wu X; Wakefield JK; Liu H; Xiao H; Kralovics R; Prchal JT; Kappes JC
Mol Ther; 2000 Jul; 2(1):47-55. PubMed ID: 10899827
[TBL] [Abstract][Full Text] [Related]
12. Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells.
Choi JK; Hoang N; Vilardi AM; Conrad P; Emerson SG; Gewirtz AM
Stem Cells; 2001; 19(3):236-46. PubMed ID: 11359949
[TBL] [Abstract][Full Text] [Related]
13. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
ter Brake O; Berkhout B
J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
[TBL] [Abstract][Full Text] [Related]
14. [*OPCML gene transferred by recombinant lentiviruses in vitro and its inhibition to ovarian cancer cells].
Yao DS; Li L; Garson K; Vanderhyden BC
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):333-8. PubMed ID: 16762191
[TBL] [Abstract][Full Text] [Related]
15. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.
Schambach A; Mueller D; Galla M; Verstegen MM; Wagemaker G; Loew R; Baum C; Bohne J
Gene Ther; 2006 Nov; 13(21):1524-33. PubMed ID: 16763662
[TBL] [Abstract][Full Text] [Related]
16. Generation of lentivirus vectors using recombinant baculoviruses.
Lesch HP; Turpeinen S; Niskanen EA; Mähönen AJ; Airenne KJ; Ylä-Herttuala S
Gene Ther; 2008 Sep; 15(18):1280-6. PubMed ID: 18463689
[TBL] [Abstract][Full Text] [Related]
17. Expression and recombination of the EGFP and EYFP genes in lentiviral vectors carrying two heterologous promoters.
Dijon M; Torne-Celer C; Moreau T; Tonnelle C; Chabannon C
Cytotherapy; 2005; 7(5):417-26. PubMed ID: 16236631
[TBL] [Abstract][Full Text] [Related]
18. Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression.
Mitta B; Weber CC; Rimann M; Fussenegger M
Nucleic Acids Res; 2004 Jul; 32(12):e106. PubMed ID: 15258250
[TBL] [Abstract][Full Text] [Related]
19. A stable system for the high-titer production of multiply attenuated lentiviral vectors.
Klages N; Zufferey R; Trono D
Mol Ther; 2000 Aug; 2(2):170-6. PubMed ID: 10947945
[TBL] [Abstract][Full Text] [Related]
20. Production of lentiviral vectors for transducing cells from the central nervous system.
Li M; Husic N; Lin Y; Snider BJ
J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
